This article is more than 5 years old. Information may no longer be current.

MacuSight reports positive phase 1 results for sirolimus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

UNION CITY, Calif. — MacuSight reported positive preliminary data from a phase 1 trial of sirolimus, an immunosuppressant and antiangiogenic drug being developed for treating macular edema resulting from age-related macular degeneration, the company announced in a press release.

The trial assessed the safety, tolerability and biological activity of sirolimus (rapamycin) administered either subconjunctivally or intravitreally to 30 patients who had wet AMD.

Investigators found that the drug was well-tolerated at all doses for both administration methods tested, with no reported IOP elevations, inflammatory effects or indications of cataract progression. In addition, all patients showed improvements in visual acuity and reductions in retinal thickness, according to the release.

The preliminary results are similar to results from MacuSight’s phase 1 study of sirolimus in diabetic macular edema (DME) patients.

“Based on the positive findings from both our wet AMD and DME studies, we are preparing to initiate phase 2 trials in both of these important indications, as well as additional ocular diseases and conditions,” said Joel Naor, MD, MacuSight’s chief medical officer, in the release.